CA-FORESCOUT-TECH
14.6.2022 12:02:08 CEST | Business Wire | Press release
Forescout Technologies , the leader in automated cybersecurity, today announced the expansion of its Envision Channel Program, launching a new Managed Service Provider (MSP) Partner Program to support customers with enhanced technical and professional service capabilities.
Designed to offer Forescout’s most experienced and technically competent partners new flexible licensing options, consumption billing, and specialized resources, the MSP program expansion improves the partner-owned customer deployment and support experience. Forescout Partners, such as BT and Accenture, were instrumental in driving program enhancements to meet the increasing security challenges of their global customers.
Kevin Brown, Managing Director, Security for BT, said: “Cybersecurity is top of mind for our customers, who all want to ensure they’ve got the best protections for their most critical assets. BT has partnered with Forescout for several years, and we have more than 50 Forescout-accredited technical professionals supporting customer deployments around the world. This new program enhancement aligns with our customers’ demand for faster, more integrated solutions that tackle the changing threat landscape and enable their opportunities.”
“Forescout’s channel program has played a pivotal role in our company’s business journey. Our channel partners have helped countless enterprises around the globe obtain more visibility of their cyber assets to quickly mitigate critical risks,” said Keith Weatherford, vice president of worldwide channel sales, Forescout. “The evolving digital terrain is creating new demand to activate Forescout services and capabilities so these new initiatives will provide a seamless set of training and enablement resources to support them on this path.”
“We see this program as a great extension of the value we have been delivering to clients in partnership with Forescout,” said Jamie Bass, Managing Director, Security, Accenture. “Allowing an organization to more easily leverage Forescout’s industry leading capabilities in network visibility as a service supported by our global delivery team reduces the requirement to hire and train an organization’s own team to deploy and run the solution.”
The Forescout Envision Channel Program now encompasses:
- Managed Services and Service Delivery Partner Program: Exclusively for partners who have demonstrated a high level of technical expertise and proficiency when deploying and supporting the Forescout platform. It provides highly qualified partners with flexible licensing and billing options in exchange for owning the customer support experience
- Updated Partner Portal and New Forescout Academy Platform: Quick access to digitally rich learning resources and assets to demonstrate and be recognized for technical competencies across the Forescout platform and broad set of capabilities.
- Partner Learning Journey Expansion: As part of the new direction for the Envision Channel Program, Forescout has developed an Accredited Engineer course for technical partner staff to be introduced to the Forescout Continuum Platform. Additionally, it has created the Forescout Forerunner Program which recognizes partners who accelerate onboarding and service delivery for client end-users.
With its new accreditations for partner engineer and technical support and new Managed Service Program, Forescout is recognizing and rewarding its global partner ecosystem to drive new earning opportunities and recognize the value add that they bring to the company’s success.
To learn more about Forescout’s Envision Channel Program, visit: https://www.forescout.com/resources/managed-service-provider-partner-program-overview/
About Forescout
Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides 100% asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom